Actively Recruiting
A Study of Fruquintinib Plus Chemotherapy for Postoperative Treatment of HER2-Negative Gastric Cancer With Poor TRG
Led by Henan Cancer Hospital · Updated on 2025-01-14
69
Participants Needed
1
Research Sites
172 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Given that a significant proportion of locally advanced gastric cancer patients still die from tumor recurrence after surgery, with long-term therapeutic outcomes stagnating and difficult to further improve, especially for patients with poor tumor regression grade (TRG) after surgery, this study aims to explore a new model of adjuvant therapy by conducting research on the use of Fruquintinib in combination with standard chemotherapy for postoperative treatment of HER2-negative gastric cancer patients with poor TRG, in order to bring greater survival benefits to patients.
CONDITIONS
Official Title
A Study of Fruquintinib Plus Chemotherapy for Postoperative Treatment of HER2-Negative Gastric Cancer With Poor TRG
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Fully understand the study and voluntarily sign the informed consent form
- Age between 18 and 75 years
- Histologically confirmed resectable or potentially resectable locally advanced gastric/gastroesophageal junction adenocarcinoma
- Tumor Regression Grade (TRG) 2 or 3 after preoperative adjuvant therapy
- R0 resection after neoadjuvant chemotherapy
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
- Life expectancy of at least 2 years
- No prior anti-cancer treatment received
- Good compliance and cooperation with follow-up
You will not qualify if you...
- Inability to comply with the study protocol or procedures
- History of prior gastric cancer surgery
- Contraindications to surgical treatment and chemotherapy or physical condition and organ function that do not allow for major abdominal surgery
- Distant metastasis to organs other than the liver, such as lung, brain, and bone
- Known HER2-positive patients
- Uncontrolled hypertension despite medication prior to enrollment
- Poorly controlled diabetes despite medication prior to enrollment
- Urine routine indicating proteinuria 652+, and a 24-hour urine protein quantification >1.0g
- Presence of conditions requiring intervention such as bleeding, perforation, or obstruction prior to enrollment
- Patients deemed ineligible for this study by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Henan Cancer Hospital
Zhengzhou, China
Actively Recruiting
Research Team
F
Fei Ma, M.D.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here